Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Valneva SECHIX:VLAP 64 EV-to-OCF is -12.05 as of Aug. 02, 2026. GuruFocus rates CHIX:VLAP with a GF Score™ of 64/100 and a GF Value™ of €2.52 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,410 Biotechnology companies, Valneva SE ranks better than 74.04% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Valneva SE's Enterprise Value is €542.9 Mil.
Valneva SE's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was €-45.1 Mil. Therefore, Valneva SE's EV-to-OCF for today is -12.05.
The historical rank and industry rank for Valneva SE's EV-to-OCF or its related term are showing as below:
CHIX:VLAp'
s EV-to-OCF Range Over the Past 10 Years
Min: -73.54 Med: 6.4 Max: 730.26
Current: -12.05
During the past 13 years, the highest EV-to-OCF of Valneva SE was 730.26. The lowest was -73.54. And the median was 6.40.
CHIX:VLAp's EV-to-OCF is ranked better than 74.04% of 1410
companies
in the Biotechnology industry
Industry Median: -3.23
vs CHIX:VLAp: -12.05
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Valneva SE's share price for today is €2.241.
Valneva SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.800.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Valneva SE EV-to-OCF Related Terms
Valneva SE EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Valneva SE's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:VLAP vs VRTX, REGN, RVMD: EV-to-OCF Comparison
For the Biotechnology subindustry, Valneva SE's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valneva SE EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valneva SE's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Valneva SE's EV-to-OCF falls into.
Valneva SE's current Enterprise Value is €542.9 Mil.
Valneva SE's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-45.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valneva SE (CHIX:VLAP) has a EV-to-OCF of -12.05 as of Aug. 02, 2026. According to the industry distribution chart, Valneva SE ranks #366 out of 1410 companies in the Biotechnology industry, placing it in the top 26%.
Is Valneva SE's EV-to-OCF too high?
Valneva SE's current EV-to-OCF is -12.05. Based on the distribution chart, Valneva SE ranks #366 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Valneva SE has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valneva SE ranks #366 out of 1410 companies for EV-to-OCF. This puts Valneva SE in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Valneva SE's current EV-to-OCF is -12.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (CHIX:VLAP) is currently considered Fairly Valued. The stock's GF Value™ is €2.52, compared to a current price of €2.24 — trading 11.1% below its estimated fair value. The current EV-to-OCF is -12.05. Valneva SE's overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Valneva SE (CHIX:VLAP), the current EV-to-OCF is -12.05 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valneva SE (CHIX:VLAP) Overvalued in 2026?
Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued.
The current stock price of €2.24 is trading 11.1% below its estimated GF Value™ of €2.52.
GuruFocus considers Valneva SE to be Fairly Valued.
Key valuation signals for CHIX:VLAP:
EV-to-OCF: -12.05
GF Value™: €2.52 vs. price of €2.24 (11.1% below fair value)
No single metric tells the full story. See the CHIX:VLAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
64GF Score
Get the complete analysis for CHIX:VLAP
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:VLAP has been successfully added to your 
